The month ahead: January’s upcoming events
Investors will hope for a JP Morgan buying spree, while readouts could come from Kura, Allogene and MacroGenics.
Conjugates enter their first clinical trials
Two Kelun ADCs and two actinium-based radioconjugates start phase 1.
Another pan-KRAS project enters the clinic
Quanta now has a “G12V-preferring” multi-KRAS asset on its clinical roster.
BioNTech's pivotal bispecifics plan take shape
Phase 3 development plans for BNT327 and ivonescimab start to diverge.
FDA red and green lights: November 2024
Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.
The month ahead: December’s upcoming events
Party season approaches; but first, conferences.
